A prospective study of detection of pancreatic carcinoma by combined plasma K-ras mutations and serum CA19-9 analysis

Pancreas

Volumn 25, Issue 4, 2002, Pages 336-341

  Dianxu, Feng ^a   Shengdao, Zhang ^a   Tianquan, Han ^a   Yu, Jiang ^a   Ruoqing, Lei ^a   Zurong, Yuan ^a   Xuezhi, Wang ^a  

^a Shanghai Putuo District Central Hospital   (China)

Author keywords

CA19 9; Gene mutation; K ras; Pancreatic carcinoma; Plasma

Indexed keywords

CA 19-9 ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER DIAGNOSIS; CODON; CONTROLLED STUDY; DIAGNOSTIC VALUE; DNA EXTRACTION; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; ONCOGENE K RAS; PANCREAS CARCINOMA; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; AGED; BASE SEQUENCE; CA-19-9 ANTIGEN; CARCINOMA; DNA; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, RAS; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; POINT MUTATION;

EID: 0036829637     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-200211000-00003     Document Type: Article

References (31)

1. Jin F, Devesa SS, Chow WH, et al. Cancer incidence trends in urban Shanghai, 1972-1994: An update. Int J Cancer 1999;83:435-40.
2. Department of Epidemiology, Shanghai Cancer Institute. 1995 Incidence of malignant tumors in Shanghai urban district. Tumor (Shanghai) 1998;18:i2.
3. Department of Epidemiology, Shanghai Cancer Institute. 1998 Incidence of malignant tumors in Shanghai urban district. Tumor (Shanghai) 2001;21:312.
4. Rosewicz S, Wiedenmann B. Pancreatic carcinoma. Lancet 1997;349:485-9.
5. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992;326:455-65.
6. Moossa AR, Gamagami RA. Diagnosis and staging of pancreatic neoplasmas. Surg Clin North Am 1995;75:871-90.
7. Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-54.
8. Grunewald K, Lynons J, Frohlich A, et al. High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 1989;43:1037-41.
9. Cerny WL, Mangold KA, Scarpelli DG. K-ras mutation is an early event in pancreatic duct carcinogenesis in the Syrian golden hamster. Cancer Res 1992;52:4507-13.
10. Tsutsumi M, Kondoh S, Noguchi O, et al. K-ras gene mutation in early ductal lesions induced in a rapid production model for pancreatic carcinomas in Syrian hamster. Jpn J Cancer Res 1993;84:1101-5.
11. Lemoine NR, Jain S, Hughes CM, et al. K-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology 1992;102:230-6.
12. Shibata D, Almoguera C, Forrester K, et al. Detection of c-K-ras mutation in fine needle aspirates from human pancreatic adenocarcinomas. Cancer Res 1990;50:1279-83.
13. Kondo H, Sugano K, Fukayama N, et al. Detection of point mutations in the K-ras oncogene at codon 12 in pure pancreatic juice for diagnosis of pancreatic carcinoma. Cancer 1994;73:1589-94.
14. Iguchi H, Sugano K, Fukayama N, et al. Analysis of Ki-ras codon 12 mutations in the duodenal juice of patients with pancreatic cancer. Gastroenterology 1996;110:221-6.
15. Shapiro B, Chakrabarty M, Cohn EM, Leon SA. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer 1983;51:2116-20.
16. Leon SA, Shapiro B, Sklaroff DM, et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977;37:646-50.
17. Stroun M, Anker P, Maurice P, et al. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 1989;46:318-22.
18. Chen XQ, Stroun M, Magnenat JL, et al. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med 1996;2:1033-5.
19. Nawroz H, Koch W, Anker P, et al. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med 1996;2:1035-7.
20. Anker P, Lefort F, Vasioukhin V, et al. K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. Gastroenterology 1997;112:1114-20.
21. Kopreski MS, Benko FA, Kwee C, et al. Detection mutant K-ras DNA in plasma or serum of patients with colorectal cancer. Br J Cancer 1997;76:1293-9.
22. Dillon DA, Salem R, Andersen D. et al. K-ras mutations are DNA tumor markers in serum and plasma of patients with cancer of the colon or pancreas. Abstr N Engl Cancer Soc 1997:37.
23. Mulcahy HE, Lyautey J, Lederrey C, et al. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin Cancer Res 1998;4:271-5.
24. Yamada T, Nakamori S, Ohzato H, et al. Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: Correlation with clinicopathologic features. Clin Cancer Res 1998;4:1527-32.
25. Castells A, Puig P, Mora J, et al. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: Diagnostic utility and prognostic significance. J Clin Oncol 1999;17:578-84.
26. Theodor L, Melzer E, Sologov M, et al. Detection of pancreatic carcinoma: Diagnostic value of K-ras mutations in circulating DNA from serum. Dig Dis Sci 1999;44:2014-9.
27. Sorensonl GD. Detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer. Clin Cancer Res 2000;6:2129-37.
28. Wong IH, Lo YM, Zhang J, et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res 1999;59:71-3.
29. Tada M, Omata M, Kawai S, et al. Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res 1993;53:2472-4.
30. Urrutia R, DiMagno EP. Genetic markers: The key to early diagnosis and improved survival in pancreatic cancer? Gastroenterology 1996;110:306-10.
31. Chu TM. Molecular diagnosis of pancreas carcinoma. J Clin Lab Anal 1997;11:225-31.